OKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
27 Abril 2022 - 3:00AM
OKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations
at the 2022 Association for Research in Vision and Ophthalmology
(ARVO) Annual Meeting
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology
company focused on the discovery and development of novel molecules
to treat inflammatory dry eye diseases and ocular pain, today
announced that two presentations will be given on OKYO drug
candidates OK-101 and OK-201 at the Association for Research and
Vision in Ophthalmology (ARVO) Annual Meeting, to be held on May
1-4, 2022 in Denver, CO and virtually on May 11-12, 2022.
The oral presentation will highlight the ability
of OK-101, a novel agonist of the chemerin receptor ChemR23, to
reduce neuropathic corneal pain (NCP) in a mouse model of ciliary
nerve ligation; and the second presentation which will be given as
a poster, will present the efficacy data of OK-201, a BAM8-22
peptide analog, in alleviating neuropathic corneal pain in the same
mouse model. These studies were conducted in collaboration with
Pedram Hamrah, MD, Interim Chair of Ophthalmology, cornea
specialist, and clinician-scientist at Tufts Medical Center,
Boston, MA using a mouse model of NCP developed in Dr. Hamrah’s
laboratory.
The presentation details are as follows:
Presentation Type: Paper Session Presentation Number:
1834Title: OK-101, A Novel Chemerin Receptor Agonist, Ameliorates
Neuropathic Corneal Pain in a Mouse Model of Ciliary Nerve
Ligation Presenter: Harris, Deshea, Department of
Ophthalmology, Tufts Medical Center, Boston, MAPresentation Date
and Time: May 2, 2022, from 4:08 PM to 4:25 PM MDTPresentation
Type: Poster SessionPosterboard Number: 1227 – A0227 Title:
Proenkephalin-derived BAM8-22 peptide analogue alleviates
neuropathic corneal pain in mice Presenter: Ayesha Sultan,
Department of Ophthalmology, Tufts Medical Center, Boston, MA
Poster Session Date/Times: May 2, 2022, from
10:00 AM to 12:00 PM MDT
About OKYO
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is
a life sciences and biotechnology company admitted to listing on
the standard segment of the Official List of the UK Financial
Conduct Authority and to trading on the main market for listed
securities of London Stock Exchange plc. OKYO is focusing on the
discovery and development of novel molecules to treat inflammatory
dry eye diseases and ocular pain.
About Ocular Pain
Ocular pain is one of the most common causes for
patient referral to the emergency clinic, with substantial
implications to global quality of life and healthcare cost.
Millions of people suffer from ocular pain every year with no
treatment approved by the U.S. Food and Drug Administration for
this condition. Side effects and the risk of addiction to opioids
is a serious concern. Ocular pain may arise directly from tissue
damage at the ocular surface after surgery, injury, infection or
from changes to peripheral or central nerves in the ocular surface.
Ocular neuropathic pain refers to the increased perception of pain
in response to ordinarily non-painful stimuli and is often
misdiagnosed as dry eye disease. Current treatments are limited to
short term non-steroidal anti-inflammatory drugs, steroids, and
oral gabapentin and opioids in severe cases.
About OK-101
OK-101 is a novel long-acting G protein-coupled
receptor-based lipidated chemerin peptide developed to bind to
ChemR23 receptors typically found on immunological cells present in
the eye. ChemR23 plays an important role in the inflammatory
response, and binding of OK-101 to ChemR23 has been shown to
produce anti-inflammatory activity in mouse models of dry-eye
disease. OK-101 was developed using a membrane-anchored-peptide
(MAP) technology to produce a long-acting drug candidate designed
to combat washout through the inclusion of a lipid ‘anchor’ within
its molecular structure to enhance residence time on the ocular
surface.
About OK-201
MAS-Related G Protein-Coupled Receptors, or
MRGPRs, mainly expressed in the sensory neurons, are involved in
the perception of pain, thus making them a promising analgesic
target. Activation of MRGPR by Bovine Adrenal Medulla, or BAM,
peptide inhibits pain perception by modulating Ca2+ influx. OK-201,
a BAM peptide analogue, is a potent agonist of human MRGPR and a
promising candidate for the treatment of neuropathic and
inflammatory pain.
Forward-Looking Statements
Certain statements made in this announcement are
forward-looking statements. These forward-looking statements are
not historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders
and prospective security holders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
For further information, please visit the
Company's website at www.okyopharma.com.
Okyo Pharma (LSE:OKYO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Okyo Pharma (LSE:OKYO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024